Should You Buy Novartis AG (NVS) Stock After it Has Gained 3.62% in a Week?

The market has been high on Novartis AG (NVS) stock recently. NVS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Novartis AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NVS!

See Full NVS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NVS Stock Today?

Novartis AG (NVS) stock has gained 0.96% while the S&P 500 is down -0.7% as of 9:34 AM on Monday, Dec 5. NVS is higher by $0.86 from the previous closing price of $89.99 on volume of 19,917 shares. Over the past year the S&P 500 is down -11.94% while NVS is higher by 12.82%. NVS earned $9.71 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 9.38. To see InvestorsObserver's Sentiment Score for Novartis AG click here.

More About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue. Click Here to get the full Stock Report for Novartis AG stock.